Fludarabine
- Generic Name
- Fludarabine
- Brand Names
- Fludara
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12FN5O4
- CAS Number
- 21679-14-1
- Unique Ingredient Identifier
- P2K93U8740
- Background
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
- Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
- Associated Conditions
- B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
CD19-redirected Autologous Cells (CAR-CD19 T Cells)
- Conditions
- CD19 Positive Malignant B-cell Leukemia and Lymphoma
- Interventions
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT02933775
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
- Conditions
- Liver Cancer
- Interventions
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT02932956
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
- Conditions
- Acute Myeloid LeukemiaCore-Binding Factor
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 68
- Registration Number
- NCT02926586
- Locations
- 🇨🇳
Xianmin Song, Shanghai, Shanghai, China
TIL Therapy for Metastatic Renal Cell Carcinoma
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Procedure: Surgical removal of tumor tissue for T cell productionDrug: CyclophosphamideDrug: FludarabineBiological: TIL infusionDrug: Interleukin-2
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Inge Marie Svane
- Target Recruit Count
- 5
- Registration Number
- NCT02926053
- Locations
- 🇩🇰
Center for Cancer Immune Therapy Dept. of Hematology/oncology, Herlev, Denmark
Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Refractory Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 37
- Registration Number
- NCT02926833
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Stanford Cancer Center, Palo Alto, California, United States
🇺🇸H Lee Moffitt Cancer Center, Tampa, Florida, United States
The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT02924753
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)
- Conditions
- Severe Aplastic Anemia
- Interventions
- Drug: Antithymocyte Globulin (ATG)Drug: FludarabineDrug: CyclophosphamideRadiation: Total Body Irradiation (TBI)Procedure: Haplo HSCTDrug: TacrolimusDrug: Mycophenolate mofetil (MMF)Drug: G-CSF
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 32
- Registration Number
- NCT02918292
- Locations
- 🇺🇸
Johns Hopkins Unversity, Baltimore, Maryland, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸University of Florida College of Medicine, Gainesville, Florida, United States
Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis
- Conditions
- Primary MyelofibrosisSecondary Myelofibrosis
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: FludarabineDrug: Fludarabine PhosphateOther: Laboratory Biomarker AnalysisDrug: MelphalanOther: Pharmacological StudyDrug: RuxolitinibDrug: Ruxolitinib PhosphateDrug: SirolimusDrug: Tacrolimus
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT02917096
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
- Conditions
- Leukemia, LymphoidLymphoma, MalignantLeukemia, MyeloidMyelodysplastic SyndromesMyelofibrosisMultiple MyelomaWaldenstrom Macroglobulinemia
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT02916979
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 9
- Registration Number
- NCT02905188
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.